Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parecoxib versus placebo during hepatectomy in cirrhotic patients with primary liver cancer
ACTRN12610000245099Phase 4Not yet recruiting
- Sponsor
- jinmin zhang
- Start
- Apr 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of parecoxib, flurbiprofen, sufentanil and propofol in hepatocellular carcinoma (HCC) and Cirrhosis (3 arms), sponsored by jinmin zhang. Primary endpoints: Postoperative liver function and hepatocyte injury and Postoperative pain. Planned start Apr 2010; status: not yet recruiting.
02
Drugs
parecoxibflurbiprofensufentanilpropofol
03
Conditions
hepatocellular carcinoma (HCC)Cirrhosis
Beyond the preview
Go deeper on ACTRN12610000245099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000245099.